Normoxia Sverige AB
ActiveKey figures
Key figures
2025/26Summary: Normoxia Sverige AB
What kind of company is it?
Normoxia Sverige AB (org. no. 559380-8461) is a limited company (AB). The company was registered in 2022 and has existed for 4 years. Registered seat: Arvika. Industry according to Statistics Sweden: research and experimental development on biotechnology (SNI 72101).
How is the company doing financially?
The company had no net sales in financial year 2026. Financial year 2026 ended with a loss of 15 270 kr. The company was profitable in 3 of the 4 reported financial years. At the end of financial year 2026, total assets were 50 053 kr and equity 38 724 kr (equity ratio 77,4 %).
Where does the data come from and how up to date is it?
Company details and digitally filed annual reports come from the open data of the Swedish Companies Registration Office (Bolagsverket) and the industry code from Statistics Sweden (CC BY 2.5 SE); bolagsprofil.se updates them daily. The latest annual report is signed by one person. Data as of 2026-11-16. Changes, averages and ratios are calculated by bolagsprofil.se from open data and are not an official assessment.
Dividend
from the annual reportProposed dividend 200 000 kr.
Summary of annual reports2023–2026
| 2022/23 | 2023/24 | 2024/25 | 2025/26 | |
|---|---|---|---|---|
| Sales revenue | 129 000 | 156 000 | 312 000 | 0 |
| Profit for the reporting year | 95 548 | 88 970 | 214 476 | −15 270 |
| Retained earnings of previous periods | — | — | — | — |
| Total assets | 128 541 | 243 738 | 302 091 | 50 053 |
| Total liabilities | 7 993 | 34 220 | 48 098 | 11 329 |
| Total equity | 120 548 | 209 518 | 253 993 | 38 724 |
| Employees | — | — | — | — |
| Proposed dividend | — | 170 000 | 200 000 | — |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.